multispecific-antibodies
(3)
Ability Biotherapeutics
Ability Biotherapeutics (also known as Ability Biologics) is a Montreal-based biotech founded in 2023 that engineers highly selective, immune-cell-modulating antibody therapeutics for cancer and autoimmune disease. Its AbiLeap discovery engine pairs continuously learning AI with one of the largest antibody-antigen interaction databases ever assembled to generate fully human, IgG-based multispecific antibodies that sense their environment and act only where intended - so-called logic-gated therapeutics. Backed by US$18M in seed capital led by Amplitude Ventures, the company is advancing a pipeline of immuno-oncology and autoimmune candidates toward preclinical readiness.
Tentarix Biotherapeutics
Tentarix Biotherapeutics is a San Diego biotech building conditionally active, multispecific biologics that switch on only at the cells where they are needed. Its proprietary stack - the VH-Select stabilized human VH scaffold, Tentacles multifunctional molecules, and the FunctionSeq mammalian-display screening engine - lets the company discover therapies with high cell selectivity and a wider therapeutic index across oncology, immuno-oncology, and autoimmune disease. Backed by Versant Ventures, Samsara BioCapital, Amplitude Ventures, and Gilead Sciences, and partnered with AbbVie and Gilead.
Hinge Bio
Hinge Bio is a clinical-stage biotechnology company in Burlingame, California, building next-generation antibody therapeutics on its proprietary GEM-DIMER platform. The platform engineers multivalent, multispecific antibodies that bind their targets cooperatively for dramatically enhanced potency. Its lead candidate, HB2198, is a B cell-depleting agent targeting both CD19 and CD20 with enhanced natural killer cell engagement, now in Phase 1 trials for systemic lupus erythematosus and lupus nephritis. The company raised a $30M Series A led by Point72 in January 2025.